Intrapleural tissue plasminogen activator for the treatment of parapneumonic effusion

Pharmacotherapy

Volumn 30, Issue 8, 2010, Pages 855-862

  Hamblin, Susan E ^a   Furmanek, Douglas L ^a  

^a GREENVILLE HOSPITAL SYSTEM   (United States)

Author keywords

Alteplase; Empyema; Fibrinolytic; Intrapleural therapy; Parapneumonic effusion; Pleural effusion; Pulmonary; t PA; Tissue plasminogen activator

Indexed keywords

ALTEPLASE; DORNASE ALFA; FIBRIN; PLASMIN; STREPTOKINASE; TISSUE PLASMINOGEN ACTIVATOR; UROKINASE;

BLEEDING; CLINICAL FEATURE; CLINICAL TRIAL; DRUG CHOICE; DRUG CONTRAINDICATION; FIBRINOLYTIC THERAPY; HEMATURIA; HUMAN; OUTCOME ASSESSMENT; PATHOPHYSIOLOGY; PLEURA EFFUSION; REVIEW; RISK ASSESSMENT; THORAX DRAINAGE;

ANIMALS; HUMANS; PLEURAL EFFUSION; PNEUMONIA; TISSUE PLASMINOGEN ACTIVATOR; TREATMENT OUTCOME;

EID: 77955448022     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.30.8.855     Document Type: Review

References (35)

1. Light RW. Pleural effusion. N Engl J Med 2002;346:1971-7.
2. Bouros D, Tzouvelekis A, Antoniou KM, Heffner JE. Intrapleural fibrinolytic therapy for pleural infection. Pulm Pharmacol Ther 2007;20:616-26.
3. Schiza SE, Antoniou KM, Economidou FN, Siafakas NM. Pharmacotherapy in complicated parapneumonic pleural effusions and thoracic empyema. Pulm Pharmacol Ther 2005;18:381-9.
4. Colice GL, Curtis A, Deslauriers J, et al. Medical and surgical treatment of parapneumonic effusions: an evidence-based guideline. Chest 2000;118:1158-71.
5. Schiza S, Siafakas NM. Clinical presentation and management of empyema, lung abscess and pleural effusion. Curr Opin Pulm Med 2006;12:205-11.
6. Chapman SJ, Davies RJO. Recent advances in parapneumonic effusion and empyema. Curr Opin Pulm Med 2004;10:299-304.
7. Light RW. A new classification of parapneumonic effusions and empyema. Chest 1995;108:299-301.
8. Misthos P, Evangelos S, Knostantinou M, Athanassiadi K, Skottis I, Lioulias A. Early use of intrapleural fibrinolytics in the management of postpneumonic empyema: a prospective study. Eur J Cardiothor Surg 2005;28:599-603.
9. Jerjes-Sanchez C, Ramirez-Rivera A, Elizalde JJ, et al. Intrapleural fibrinolysis with streptokinase as an adjunctive treatment in hemothorax and empyema. Chest 1996;109:1514-19.
10. Chin NK, Lim TK. Controlled trial of intrapleural streptokinase in the treatment of pleural empyema and complicated parapneumonic effusions. Chest 1997;111:275-9.
11. Hsu LH, Soong TC, Feng AC, Liu MC. Intrapleural urokinase for the treatment of loculated malignant pleural effusions and trapped lungs in medically inoperable cancer patients. J Thorac Oncol 2006;1:460-7.
12. Bouros D, Schiza S, Tzanakis N, Chalkiadakis G, Drositis J, Siafakas N. Intrapleural urokinase versus normal saline in the treatment of complicated parapneumonic effusions and empyema: a randomized, double-blind study. Am J Respir Crit Care Med 1999;159:37-42.
13. Cameron R, Davies HR. Intra-pleural fibrinolytic therapy versus conservative management in the treatment of adult parapneumonic effusions and empyema. Cochrane Database Syst Rev 2008;(2):CD002312.
14. Maskell NA, Davies C, Nunn AJ, et al. U.K. controlled trial of intrapleural streptokinase for pleural infection. N Engl J Med 2005;352:865-74.
15. Tokuda Y, Matsushima D, Stein G, Miyagi S. Intrapleural fibrinolytic agents for empyema and complicated parapneumonic effusions: a meta-analysis. Chest 2006;129:783-90.
16. Wait MA, Sharma S, Hohn J, Nogare AD. A randomized trial of empyema therapy. Chest 1997;111:1548-51.
17. Landreneau R, Keenan R, Hazelrigg S, Mack M, Naunheim K. Thoracoscopy for empyema and hemothorax. Chest 1995;109:18-24.
18. Scherer LA, Battistella F, Owings J, Aguilar M. Videopassisted thoracic surgery in the treatment of posttraumatic empyema. Arch Surg 1998;133:637-42.
19. Longstaff C, Williams S, Thelwell C. Fibrin binding and the regulation of plasminogen activators during thrombolytic therapy. Cardiovasc Hematol Agents Med Chem 2008;6:212-23.
20. Bouros D, Schiza S, Siafakas N. Use of purified streptokinase in empyema and hemothorax. Am J Surg 1991;161:560-2.
21. Bouros D, Schiza S, Siafakas N. Utility of fibrinolytic agents for draining intrapleural infections. Semin Respir Infect 1999;14:39-47.
22. Heppler JS. Intrapleural fibrinolytics for pleural infection: optimizing dosing for future trials [letter]. Mayo Clin Proc 2007;82:1013-17.
23. Gervais DA, Levis DA, Hahn PF, Uppot RN, Arellano RS, Mueller PR. Adjunctive intrapleural tissue plasminogen activator administered via chest tubes placed with imaging guidance: effectiveness and risk for hemorrhage. Radiology 2008;246:956-63.
24. Levinson GM, Pennington DW. Intrapleural fibrinolytics combined with image-guided chest tube drainage for pleural infection. Mayo Clin Proc 2007;82:407-13.
25. Skeete D, Rutherford E, Schlidt S, Abrams J, Parker L, Rich P. Intrapleural tissue plasminogen activator for complicated pleural effusions. J Trauma 2004;57:1178-83.
26. Thommi G, Nair C, Aronow W, Shehan C, Meyers P, McLeay M. Efficacy and safety of intrapleural instillation of alteplase in the management of complicated pleural effusion or empyema. Am J Ther 2007;14:341-5.
27. Emerson C, Bercume C, Antonopoulos M, Marzella N. The administration of rt-PA (Activase) for the treatment of empyema in an adult patient. J Pharm Pract 2009;22:117-23.
28. Walker C, Shirk M, Tschampel M, Visconti J. Intrapleural alteplase in a patient with complicated pleural effusion. Ann Pharmacother 2003;37:376-9.
29. Thommi G, Shehan C, Meyers P, Mcleay M. Intrapleural instillation of alteplase in complicated malignant pleural effusions prior to pleurodesis [abstract]. Chest 2004;126(suppl):892S.
30. Davies R, Traill Z, Gleeson F. Randomized controlled trial of intrapleural streptokinase in community acquired pleural infection. Thorax 1997;52:416-21.
31. Berglin E, Ekroth R, Teger-Nilsson A, William-Olsson G. Intrapleural instillation of streptokinase effects on systemic fibrinolysis. Thorac Cardiovasc Surg 1981;29:124-6.
32. Zhu Z, Hawthorne M, Guo Y, et al. Tissue plasminogen activator combined with human recombinant deoxyribonuclease is effective therapy for empyema in a rabbit model. Chest 2006;129:1577-83.
33. Simpson G, Roomes E, Reevew B. Successful treatment of empyema thoracis with human recombinant deoxyribonuclease. Thorax 2000;58;365-6.
34. U.S. National Institutes of Health. ClinicalTrials.gov. Available from www.clinicaltrials.gov. Accessed June 30, 2009.
35. Medical Research Council, Clinical Trials Unit. The second multicenter intrapleural sepsis trial (MIST2). Available from http://www.ctu.mrc.ac.uk/ research-areas/study-details.aspx?s=46. Accessed June 30, 2009.